Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Michael J Wagner; Megan Othus; Sandip P Patel; Chris Ryan; Ashish Sangal; Benjamin Powers; G Thomas Budd; Adrienne I Victor; Chung-Tsen Hsueh; Rashmi Chugh; Suresh Nair; Kirsten M Leu; Mark Agulnik; Elad Sharon; Edward Mayerson; Melissa Plets; Charles Blanke; Howard Streicher; Young Kwang Chae; Razelle Kurzrock

doi:10.1136/jitc-2021-002990

Article info

PDF

PDF +
Supplementary
Material

XML

Clinical/translational cancer immunotherapy

Original research

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Authors

Michael J Wagner Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USAMedical Oncology, University of Washington, Seattle, Washington, USA PubMed articles Google scholar articles
Megan Othus SWOG Statistical and Data Management Center/Fred Hutchinson Cancer Research Center, Seattle, Washington, USA PubMed articles Google scholar articles
Sandip P Patel Department of Medicine, UCSD Moores Cancer Center, La Jolla, California, USA PubMed articles Google scholar articles
Chris Ryan Department of Medicine, OHSU, Portland, Oregon, USA PubMed articles Google scholar articles
Ashish Sangal Western Regional Medical Center, Goodyear, Arizona, USA PubMed articles Google scholar articles
Benjamin Powers Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA PubMed articles Google scholar articles
G Thomas Budd Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio, USA PubMed articles Google scholar articles
Adrienne I Victor Department of Medicine, University of Rochester, Rochester, New York, USA PubMed articles Google scholar articles
Chung-Tsen Hsueh Loma Linda University, Loma Linda, California, USA PubMed articles Google scholar articles
Rashmi Chugh Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA PubMed articles Google scholar articles
Suresh Nair Lehigh Valley Health Network, Allentown, Pennsylvania, USA PubMed articles Google scholar articles
Kirsten M Leu Nebraska Methodist Health System, Omaha, Nebraska, USA PubMed articles Google scholar articles
Mark Agulnik Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USADepartment of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articles Google scholar articles
Elad Sharon Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA PubMed articles Google scholar articles
Edward Mayerson SWOG Statistical and Data Management Center/Fred Hutchinson Cancer Research Center, Seattle, Washington, USA PubMed articles Google scholar articles
Melissa Plets SWOG Statistical and Data Management Center/Fred Hutchinson Cancer Research Center, Seattle, Washington, USA PubMed articles Google scholar articles
Charles Blanke Department of Medicine, OHSU, Portland, Oregon, USASWOG, Portland, Oregon, USA PubMed articles Google scholar articles
Howard Streicher Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA PubMed articles Google scholar articles
Young Kwang Chae Department of Medicine, Northwestern University, Chicago, Illinois, USA PubMed articles Google scholar articles
Razelle Kurzrock Department of Medicine, UCSD Moores Cancer Center, La Jolla, California, USA PubMed articles Google scholar articles

Citation

Wagner MJ, Othus M, Patel SP, et al

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Journal for ImmunoTherapy of Cancer 2021;9:e002990. doi: 10.1136/jitc-2021-002990

Online issue publication

November 02, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password